Genitourinary Cancer
Conference Coverage
Antibiotic use may hamper checkpoint inhibitors for mRCC
The first study to examine the potential impact of broad-spectrum antibiotic therapy in the era of immune checkpoint inhibitors suggests a...
Conference Coverage
Circulating tumor DNA could guide therapy for advanced prostate cancer
One of the largest studies to look at circulating tumor DNA in advanced prostate cancer supports the promise of using blood sample assays to...
Conference Coverage
Staying the course after first progression yields better mRCC survival
AMSTERDAM – mRCC patients who stayed on the same targeted therapy after first progression had better overall survival than did those who switched...
Conference Coverage
GU Cancers Symposium to feature latest on immune checkpoint inhibitors, circulating tumor cells
Oncology Practice will be on site this coming week at the 2017 Genitourinary Cancers Symposium in Orlando.
News from the FDA/CDC
FDA approves nivolumab for advanced urothelial carcinoma
The recommended dose for advanced urothelial carcinoma is 240 mg intravenously every 2 weeks.
From the Journals
Antiandrogen therapy improves survival after biochemical recurrence of prostate cancer
Adding antiandrogen treatment to salvage radiotherapy markedly improves long-term survival and disease-specific mortality, reduces the rate of...
Conference Coverage
Coming Soon!
Watch for our onsite coverage of the 2017 Genitourinary Cancers Symposium, which will take place in Orlando February 16-18.
From the Journals
ASCO offers practice guidance on small renal masses
All patients with small renal masses detected on imaging should be considered for renal tumor biopsy when there is a likelihood that the results...
From the Journals
AKT inhibition not superior to everolimus for RCC
The AKT inhibitor MK-2206 was not superior to everolimus for patients with metastatic renal cell carcinoma refractory to vascular endothelial...
From the Journals
Adjuvant chemo prolonged survival after radical nephroureterectomy
Adjuvant chemotherapy prolonged survival after radical nephroureterectomy by nearly a year, compared with observation alone, among patients with...